- Home
- RDIB vs SLN Comparison
RDIB vs SLN Comparison
Compare RDIB & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- SLN
- Stock Information
- Founded
- RDIB 1937
- SLN 1994
- Country
- RDIB United States
- SLN United Kingdom
- Employees
- RDIB N/A
- SLN N/A
- Industry
- RDIB Movies/Entertainment
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- RDIB Consumer Discretionary
- SLN Health Care
- Exchange
- RDIB Nasdaq
- SLN Nasdaq
- Market Cap
- RDIB 279.6M
- SLN 268.8M
- IPO Year
- RDIB N/A
- SLN N/A
- Fundamental
- Price
- RDIB $11.55
- SLN $4.85
- Analyst Decision
- RDIB
- SLN Buy
- Analyst Count
- RDIB 0
- SLN 6
- Target Price
- RDIB N/A
- SLN $39.67
- AVG Volume (30 Days)
- RDIB 6.3K
- SLN 51.4K
- Earning Date
- RDIB 11-13-2025
- SLN 11-13-2025
- Dividend Yield
- RDIB N/A
- SLN N/A
- EPS Growth
- RDIB N/A
- SLN N/A
- EPS
- RDIB N/A
- SLN N/A
- Revenue
- RDIB $219,213,000.00
- SLN $27,169,000.00
- Revenue This Year
- RDIB $5.21
- SLN N/A
- Revenue Next Year
- RDIB $11.45
- SLN N/A
- P/E Ratio
- RDIB N/A
- SLN N/A
- Revenue Growth
- RDIB 7.59
- SLN 22.28
- 52 Week Low
- RDIB $5.78
- SLN $1.97
- 52 Week High
- RDIB $14.95
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- RDIB 46.80
- SLN 43.68
- Support Level
- RDIB $9.99
- SLN $4.42
- Resistance Level
- RDIB $12.91
- SLN $5.80
- Average True Range (ATR)
- RDIB 0.77
- SLN 0.36
- MACD
- RDIB -0.17
- SLN -0.02
- Stochastic Oscillator
- RDIB 42.62
- SLN 31.16
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.